Ascletis Pharmaceuticals Co., Ltd.
Clinical trials sponsored by Ascletis Pharmaceuticals Co., Ltd., explained in plain language.
A biopharmaceutical company developing targeted cancer therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New pill shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested a new daily pill, ASC61, in 18 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check the drug's safety and how the body processes it. Researchers looked for side effects and measured tumor respons…
Phase 1 • Sponsor: Ascletis Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New acne pill tested for Long-Term safety in 240 patients
Disease control CompletedThis study tested the long-term safety of a daily pill called ASC40 (Denifanstat) in 240 people with moderate to severe acne who had already completed a previous phase 3 trial. Participants took the drug once daily for up to 40 weeks, with regular blood tests and checkups to moni…
Phase 3 • Sponsor: Ascletis Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC